Replies to post #6305 on Biotech Values

[mskatiescarletohara]

Bladerunner...

I was simply commenting on the Yahoo chatter. You know as well as I, it was one of the best boards to read on Yahoo, there are some fine fine posters over there. I was just commenting on the redundancy there. I'm well aware of the risks etc, I just tire of reading the same stuff over and over again. It gets old punkin!

I think you put too much faith in Dr. Garren. I view Lilly's failure as neutral for COR. Tollefson is an asset, no question, maybe they can get this ampakine version to be a success. COR will turn the page when they have success in the clinic. Period.

Happy New Year to you too....

katie...

[DewDiligence]

Bladerunner, I was planning a detailed reply but Katie said it all succinctly in #6312. The most important point she made –which I strongly agree with— is that LLY’s failure with high-impact Ampakines is double-edged, not positive, for COR.

[drbio45]

I don't own much cor

but I will buy more on any weakness. Risk reward is substantial in this case